RxDoctor Payments Data

Darlene Popat, MD

Cardiovascular Disease · Melbourne, FLNPI 1225030513

Payments from drug & device makers

$1,389in general payments, 2019–2025

Across 62 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$224
  • AstraZeneca$205
  • Boehringer Ingelheim$140
  • Amgen$128
  • Pfizer$111
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$72
  • plus $510 from 16 others

What the payments were for

  • Food & beverage$1,30094%
  • Education$896%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,389 in reported general payments places this provider in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$189,691
Medicare patients
754
Services billed
2,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban476$477,934
EntrestoSacubitril/Valsartan91$92,700
XareltoRivaroxaban75$85,028
FarxigaDapagliflozin Propanediol77$64,462
JardianceEmpagliflozin27$43,478
Repatha SureclickEvolocumab49$31,290
BrilintaTicagrelor33$20,427
Praluent PenAlirocumab18$11,698
Metoprolol Succinate279$4,032
Amiodarone Hcl165$2,964
Flecainide Acetate83$2,949
Labetalol Hcl102$2,704
Enoxaparin Sodium46$2,435
Losartan Potassium227$2,274
Atorvastatin Calcium192$1,790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$111$477,934476 claims
NovartisEntresto$224$92,70091 claims
Johnson & JohnsonXarelto$23$85,02875 claims
AstraZenecaFarxiga, Brilinta$205$84,889110 claims
Boehringer IngelheimJardiance$140$43,47827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →